Breast Cancer Research and Treatment

, Volume 23, Issue 1–2, pp 17–27 | Cite as

Should women with node-negative breast cancer receive adjuvant chemotherapy? — Insights from a decision analysis model

  • Bruce E. Hillner
  • Thomas J. Smith
14th Annual San Antonio Breast Cancer Symposium — Plenary Lecture


The use of adjuvant chemotherapy in women with node-negative breast cancer has been controversial and actively debated since the 1988 National Cancer Institute Clinical Alert. We developed a decision analysis model that used the results of available randomized controlled trials to assess the potential clinical and financial effects of using adjuvant chemotherapy for groups of 45-year-old and 60-year-old women. Using the baseline assumptions, we found that chemotherapy increases quality adjusted life expectancy and survival by a substantial amount at a cost comparable to most accepted medical interventions. The model highlights the uncertainties in duration of benefit from therapy, the need for refinements in risk stratification, the importance of patient preferences about toxicity and benefit, and the need for accurate cost-accounting for oncologic therapies. Decision analysis complements other methods for information gathering, analysis, and synthesis used in clinical research. With the increasing focus on the effectiveness of medical interventions, decision analysis will be an important tool for oncologists to understand.

Key words

breast neoplasm cost-effectiveness decision trees economics medical effectiveness patient preferences 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    National Cancer Institute: Clinical Alert, May 16–18, 1988. NCI, Bethesda, 1988Google Scholar
  2. 2.
    Devita VT: Breast cancer therapy: exercising all our options. N Engl J Med 320:527–529, 1989PubMedGoogle Scholar
  3. 3.
    McGuire WL: Adjuvant therapy of node-negative breast cancer. N Engl J Med 320:525–527, 1990Google Scholar
  4. 4.
    Ingle JN: Assessing the risk of recurrence in breast cancer. N Engl J Med 322:329–331, 1990PubMedGoogle Scholar
  5. 5.
    Henderson IC: Adjuvant systemic therapy: State of the art, 1989. Breast Cancer Res Treat 14:3–22, 1989PubMedGoogle Scholar
  6. 6.
    Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 324:160–168, 1991PubMedGoogle Scholar
  7. 7.
    Pauker SG, Kassirer JP: Decision analysis. N Engl J Med 316:250–258, 1987PubMedGoogle Scholar
  8. 8.
    Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S: A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7:355–366, 1989PubMedGoogle Scholar
  9. 9.
    Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187, 1989PubMedGoogle Scholar
  10. 10.
    NIH Consensus Conference: Treatment of early-stage breast cancer. JAMA 265:391–395, 1991Google Scholar
  11. 11.
    Bonadonna G: Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7:1380–1397, 1989PubMedGoogle Scholar
  12. 12.
    Norton L: Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 3:231–249, 1985Google Scholar
  13. 13.
    Norton L: Kinetic concepts in the treatment of breast cancer. Breast Cancer Res Treat, in pressGoogle Scholar
  14. 14.
    Tannock IF: Adjuvant therapy for node-negative breast cancer. N Engl J Med 321:471, 1989Google Scholar
  15. 15.
    Levine MN, Guyatt GH, Gent M, et al: Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 6:1798–1810, 1988PubMedGoogle Scholar
  16. 16.
    Levine MN: Quality of life in breast cancer.In Osoba D (ed) Effect of Cancer on Quality of Life. CRC Press, Boca Raton, 1991, pp 205–214Google Scholar
  17. 17.
    Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS: Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7:36–44, 1989PubMedGoogle Scholar
  18. 18.
    Gelber RD, Goldhirsch A, Cavalli F: Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med 114:621–628, 1991PubMedGoogle Scholar
  19. 19.
    McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006–1015, 1990PubMedGoogle Scholar
  20. 20.
    Simes RJ, Cocker K, Glasziou P, Coates AS, Tattersall MH: Costs and benefits of adjuvant chemotherapy for breast cancer: an assessment of patient preferences [abstract]. Proc Am Soc Clin Oncol 8:52A, 1989Google Scholar
  21. 21.
    Baker MS, Kessler LG, Urban N, Smucker RC: Estimating the treatment costs of breast and lung cancer. Med Care 29:40–49, 1991PubMedGoogle Scholar
  22. 22.
    Detsky AS, Nagle T: A clinician's guide to cost-effectiveness analysis. Ann Intern Med 113:147–154, 1990PubMedGoogle Scholar
  23. 23.
    Drummond MF, Stoddart GL, Torrance GW: Methods for the Evaluation of Health Care Programmes. Oxford University Press, Oxford, 1987, p 39Google Scholar
  24. 24.
    Gelber RD, Goldhirsch A: The concept of an overview of cancer clinical trials with special emphasis on early breast cancer. J Clin Oncol 4:1696–1703, 1986PubMedGoogle Scholar
  25. 25.
    Institute of Medicine: Breast Cancer: Setting Priorities for Effectiveness Research. IOM, Washington DC, 1990Google Scholar
  26. 26.
    Hillner BE, Smith TJ, Desch CE: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer — Estimates using decision analysis while awaiting clinical trial results. JAMA 267:2055–2061, 1992PubMedGoogle Scholar
  27. 27.
    Siminoff LA, Fetting JH: Effects of outcome framing on treatment decisions in the real world: Impact of framing on adjuvant breast cancer decisions. Med Decis Making 9:262–261, 1989PubMedGoogle Scholar
  28. 28.
    Fetting JH, Siminoff LA, Piantadosi S, Abeloff MD, Damron DJ, Sarsfield AM: Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study. J Clin Oncol 8:1476–1482, 1990PubMedGoogle Scholar
  29. 29.
    Hillner BE, Smith TJ: Estimating the efficacy and cost-effectiveness of tamoxifen compared to tamoxifen plus chemotherapy in node-positive, estrogen receptorpositive postmenopausal women. International Conference on Long-Term Anti-Estrogen Therapy, Orlando, Florida, June 30, 1991Google Scholar
  30. 30.
    Detsky AS: What's wrong with decision analysis? Can the left brain influence the right? J Clin Epidemiol 40:831–836, 1987Google Scholar
  31. 31.
    Welch HG, Larson EB: Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 321:807–812, 1989PubMedGoogle Scholar
  32. 32.
    Weinstein MC, Stason WB: Cost-effectiveness of coronary artery bypass surgery. Circulation 66(Suppl III):56–66, 1982Google Scholar
  33. 33.
    Edelson JT, Weinstein MC, Tosteson ANA, Williams L, Lee TH, Goldman L: Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:407–413, 1990PubMedGoogle Scholar
  34. 34.
    Strange PB, Sumner AT: Predicting treatment costs and life expectancy for end-stage renal disease. N Engl J Med 298:372–378, 1978PubMedGoogle Scholar
  35. 35.
    Eddy DM: Screening for breast cancer. Ann Intern Med 111:389–399, 1989PubMedGoogle Scholar
  36. 36.
    Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 325:81–86, 1991PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Bruce E. Hillner
    • 1
  • Thomas J. Smith
    • 2
  1. 1.Division of General Medicine, Department of Internal MedicineMedical College of Virginia, Virginia Commonwealth UniversityRichmond
  2. 2.Massey Cancer CenterMedical College of Virginia, Virginia Commonwealth UniversityRichmond

Personalised recommendations